Myokardia Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Myokardia Inc (MYOK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Myokardia Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Myokardia Inc | - | - | - | No |
| High-Confidence Competitors (104) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MYOK Stock Performance relative to its Competitors
MYOK Stock Performance relative to High-Confidence Competitors
Myokardia Inc's Competitors Named by the Company
Competitive relationships identified from Myokardia Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Cadrenal Therapeutics Inc | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Qsam Biosciences Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| AstraZeneca plc | Company report | 85% |
| Amgen, Inc. | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Intra cellular Therapies Inc | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| Cell Source Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Gilead Sciences, Inc. | Company report | 85% |
| Sanofi S.A. | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Eli Lilly and Company | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Corvus Pharmaceuticals, Inc. | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Edgewise Therapeutics inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| MNMD | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Fulgent Genetics Inc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Atlantic Coastal Acquisition Corp Ii | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Definium Therapeutics Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Redwoods Acquisition Corp | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Kura Oncology Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Adicet Bio Inc | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Tc Biopharm holdings Plc | Company report | 85% |
| Clearside Biomedical Inc | Company report | 85% |
| Scinai Immunotherapeutics Ltd | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| United Health Products Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Exscientia Plc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Eisai Co., Ltd. | Company report | 85% |
| Atreca inc | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Seagen Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Tango Therapeutics, Inc. | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Oncosec Medical Incorporated | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Rafael Holdings Inc | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Carisma Therapeutics Inc | Company report | 85% |
| Cytodyn inc | Company report | 85% |
| Exelixis, Inc. | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| Boehringer Ingelheim AG | Company report | 85% |
| RENB | Company report | 85% |
| Bayer-Schering Pharmaceutical | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Astellas Pharma Inc. | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| Syndax, Inc. | Company report | 85% |
| Nurix Therapeutics Inc | Company report | 85% |
| Mirum Pharmaceuticals Inc | Company report | 85% |
| Replimune Group Inc | Company report | 85% |
| BMS | Company report | 85% |
| Gracell Biotechnologies Inc | Company report | 85% |
| Arena Pharmaceuticals Inc | Company report | 85% |
| Celularity Inc | Company report | 85% |
| APDN | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Perspective Therapeutics Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Black Diamond Therapeutics Inc | Company report | 85% |
| Anaptysbio Inc | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Immix Biopharma Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Sage Therapeutics Inc | Company report | 85% |
| Bridgebio Pharma Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Fortress Biotech Inc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Alkermes Plc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Ovid Therapeutics Inc | Company report | 85% |
| Repare Therapeutics Inc | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Xilio Therapeutics Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Deciphera Pharmaceuticals Inc | Company report | 85% |
| Kiniksa Pharmaceuticals International Plc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Prothena Corporation Public Limited Company | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Celldex Therapeutics inc | Company report | 85% |
| Travere Therapeutics Inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Reunion Neuroscience Inc | Company report | 85% |
| Blueprint Medicines Corporation | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Merus N v | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| Prometheus Biosciences Inc | Company report | 85% |
| Affimed N v | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Alexion Pharmaceuticals Inc | Company report | 85% |
| Axsome Therapeutics Inc | Company report | 85% |
| Atara Biotherapeutics Inc | Company report | 85% |
| Biomarin Pharmaceutical Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| Harpoon Therapeutics Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Longboard Pharmaceuticals Inc | Company report | 85% |
| Cerevel Therapeutics Holdings Inc | Company report | 85% |
| Ideaya Biosciences Inc | Company report | 85% |
| Aldeyra Therapeutics Inc | Company report | 85% |
| Cogent Biosciences Inc | Company report | 85% |
| Prelude Therapeutics Inc | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
Company report basis, confidence, active dates and source counts for Myokardia Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
